Moderna and Merck cancer vaccine reduces melanoma recurrence risk by 42% in trial

Source Summary

Detailed trial data confirm that a personalized mRNA cancer vaccine developed jointly by Moderna and Merck reduced the risk of disease recurrence in melanoma patients by 42% compared to standard treatment. The vaccine met its key endpoints in the trial.

Why it matters

A 42% reduction in melanoma recurrence represents a significant clinical advance in personalized cancer treatment and validates the mRNA vaccine approach for oncology.